5. Conclusion
The use of FGF21 analogs reduced serum triglyceride levels, LDL levels,
PRO-C3 levels, and glycated hemoglobin while increasing HDL levels.
Despite no significant differences in NASH resolution and weight loss
between the FGF21 analog-treated group and the control group, these
findings suggest a potential dual benefit of FGF21 in liver health and
glycemic control. We emphasize the need for larger RCTs and do not
support the routine use of FGF21 analogs in all patients with NASH.
Instead, FGF21 analogs may be reasonable among selected low stages of
fibrosis and NASH disease, at the discretion of clinicians and patients
through shared decision-making based on individualized considerations of
treatment risks and benefits.